Unitaid and the Global Health Innovative Technology Fund strengthen ties to improve access to critical health tools

The Global Health Innovative Technology Fund (GHIT Fund) and Unitaid have signed a cooperation framework that aims to strengthen collaboration between the two agencies to increase cooperation between the Japanese research and development industry and the broader global health response. The partnership will focus on tackling complex challenges such as emerging drug resistance in tuberculosis (TB) and malaria and shifting patterns of vector-borne diseases due to climate change.

By reinforcing links between the GHIT Fund’s research and development pipeline and Unitaid’s expertise in product introduction and access, the framework will further efforts to connect partners and ideas dealing with topics of health innovation, access, and scale.

The agreement unites the two agencies at a broad strategic level and creates a channel for continuous collaboration, scanning the innovation pipeline for late-stage products that address the most pressing global health needs. This work will further efforts to ensure vulnerable and underserved populations have access to better health products and support progress toward universal health coverage.

“GHIT looks forward to strengthening the strategic partnership with United as both organizations enter the next chapter of respective 5-year strategic plans. We strive for a seamless transition of GHIT’s innovation pipelines to Unitaid’s expertise in new product introduction and access, bridging equitable and sustainable access and delivery at scale. We will accelerate the R&D pipeline to maximize impact,” said Dr. Osamu Kunii, CEO of the GHIT Fund.

“The recent COVID-19 pandemic has illustrated the importance of global collaboration in solving global problems,” said Dr. Philippe Duneton, Executive Director of Unitad. “Unitaid’s reinforced partnership with the GHIT Fund will leverage ties with Japanese innovators who are addressing some of today’s most pressing health challenges. This will improve equitable access to the benefits of new medicines, diagnostics, and health technologies for people everywhere, in pursuit of a healthier, safer world for all.”